NON-SMALL CELL LUNG CANCER (NSCLC)

This study tests a vaccine designed to help the immune system recognize and attack non-small cell lung cancer. About 30 adults with early or locally advanced lung cancer will receive the vaccine every 3 weeks for 3 doses, with optional yearly boosters for up to 5 years. The goal …

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This study tests a new drug called BMS-986523, alone or with other cancer drugs, in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change (KRAS mutation). The goal is to see if it is safe and works. About 252 adults wi…

This early-stage trial tests gilteritinib, a drug already approved for a type of leukemia, in about 40 adults with advanced ALK-positive non-small cell lung cancer whose tumors no longer respond to standard ALK inhibitors. Participants take a daily tablet, and the main goal is to…

This study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…

This early-stage trial is testing a new drug called IDE892, alone or combined with another drug (IDE397), in people with advanced solid tumors that lack a gene called MTAP. The study aims to find safe doses and see if the drugs can shrink tumors. About 260 adults with cancers lik…

This study tests a new drug called WSD0922-FU combined with the standard drug osimertinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The trial aims to see if the combination is safe and can shrink tumors. About 48 adult…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study looks at people with advanced stage IV non-small cell lung cancer that has spread. After standard therapy (chemo, immunotherapy, or targeted drugs) works well, some will also get surgery or radiation on remaining tumors. The goal is to see if this extra treatment helps…

This study tests a new oral drug called JYP0015 in adults with advanced solid tumors that have a RAS mutation, including pancreatic, lung, and colorectal cancers. The drug is designed to block multiple forms of the RAS protein, which can drive cancer growth. The trial aims to che…

This early-stage trial tests a new drug called NX-1607 in 345 adults with advanced cancers like ovarian, lung, and melanoma. The goal is to check safety and find the right dose. Participants have cancers that have not responded to standard treatments.

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. About 60 adults with operable stage IB-IIIA NSCLC will receive …

This study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS mutations. The main goal is to check the drug's safety and side effects, not to cure the cancer. Participants must …

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…

This study tests whether a new drug combo (sotorasib plus chemotherapy) works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has a specific KRAS G12C gene change and low PD-L1 levels. About 750 adults wh…

This study compares a new drug called pumitamig to the current standard drug durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have completed chemotherapy and radiation without their cancer getting worse. The goal is to see if pu…

This phase 3 study compares a new drug, pumitamig, to the standard treatment pembrolizumab in 750 people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. Participants have not had prior treatment for their advanced cancer. The goal is to se…

This early-phase study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancer that has spread or cannot be removed by surgery. The main goals are to check safety and find the best dose. About 240 participants will receive the drug, and researc…

This study tests an experimental drug called patritumab deruxtecan (HER3-DXd) in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called HER3 found on many cancer cells. About 740 participants with various cancers (inclu…

This early-phase study tests a new drug called TH9619 in people with advanced solid tumors (colorectal, head and neck, lung, or stomach cancer) that have not responded to prior treatment. The main goals are to find a safe dose and check for side effects. About 43 participants wil…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This study tests a new oral drug, STX-241, in people with advanced non-small cell lung cancer that has become resistant to standard targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. The trial aims to find the safest…

This program provides early access to two experimental immunotherapy drugs, Botensilimab and Balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have trie…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is designed to help the immune system fight cancer. The trial has two parts: first, finding the safest dose, and then seeing if it shrinks tumors. Abo…

This study tests whether the drug taletrectinib can prevent lung cancer from returning in people with a specific gene change (ROS1 fusion) after their tumor has been surgically removed. About 180 adults with stage IB to IIIA non-small cell lung cancer will receive either taletrec…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer dru…

This study tests whether a new drug combination can help people with stage III lung cancer whose disease has returned after standard treatment. Participants first receive targeted radiation, then two drugs (durvalumab and ceralasertib) to boost the immune system and block cancer …

This study tests a new drug called KO-2806 in about 300 adults with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with other cancer medicines. The main goals are to check safety and see if the drug can shrink tumors.

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if the drug can shrink tumors or slow cancer growth. All participants receive the active drug, and treatment may continue as long as it helps and side effect…

This study compares a new drug, datopotamab deruxtecan (Dato-DXd), against standard chemotherapy (docetaxel) in 400 adults with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The cancer must have a specific protein called TROP2 and n…

This study tests a new drug called RMC-5127, alone or with other medicines, in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific KRAS G12V mutation. The goal is to see if the drug is safe and can shrink tumors. About 574 particip…

This study is testing new drugs called RAS(ON) inhibitors for people with advanced non-small cell lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors or slow the cancer's growth. About 616 adults who have already tried standard tr…

This study tracks side effects, especially lung problems, in 500 Japanese people with a specific type of non-small cell lung cancer taking Brigatinib. Doctors will monitor participants for 1 year as they receive standard treatment. The goal is to better understand the drug's safe…

This study tests two new radioactive imaging agents (JFI447 and FFG233) to see how well they show up on PET scans in people with advanced solid tumors like pancreatic, lung, breast, colorectal cancers, and sarcomas. The goal is to measure how the agents spread in the body and com…

This study tests a special dye called LS301-IT that makes lung cancer cells glow during surgery. About 35 adults with early-stage non-small cell lung cancer will receive the dye before their tumor-removal surgery. The goal is to see if the dye helps surgeons find and remove all c…

This study tests whether using an incentive spirometer—a device that encourages deep breathing—can lower the risk of lung inflammation (pneumonitis) in people with advanced lung cancer receiving chemotherapy and radiation. About 100 participants will use the device 10 times every…

This observational study is following 100 adults with metastatic non-small cell lung cancer who have certain EGFR mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers want to see how long the treatment keeps the can…

This study is watching how lung cancer patients do when they get the drug tislelizumab in normal doctor visits, not in a strict research setting. About 240 people with small cell or non-small cell lung cancer will take part. The goal is to see how long they live, how the drug aff…

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The goal is to see how safe it is and how radiation from it spreads through the body. Partici…

This study explores whether genetic material (DNA and RNA) from tiny particles called extracellular vesicles, collected during a routine lung wash (bronchoalveolar lavage), can be used for genetic testing in people with advanced non-small cell lung cancer. The goal is to see if t…

This study reviews medical records of 100 adults in Taiwan with resectable non-small cell lung cancer who received nivolumab (an immunotherapy) combined with chemotherapy before surgery. Researchers want to see if this approach helps shrink tumors completely and delays cancer ret…

This study interviews 55 people — patients with early-stage non-small cell lung cancer and their doctors — to understand their views on treatment options. No new drugs are tested. The goal is to learn what matters most to patients and physicians when choosing a treatment plan.…